Cysteinyl Leukotriene Receptor Antagonism by Montelukast to Treat Visual Deficits
Journal of Ocular Pharmacology and Therapeutics · 2024
DOI: 10.1089/jop.2024.0111 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Ocular Pharmacology and Therapeutics, 2024. Verfasst von Amritha T M Seetharaman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Acetates, Cyclopropanes, Leukotriene Antagonists, Quinolines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS.
Abstract (Originalsprache)
Montelukast, a Food and Drug Administration-approved drug for asthma and allergic rhinitis modulates leukotriene (LT) receptors and serves as a critical anti-inflammatory agent. Recent research suggests that the LT signaling pathway targeted by montelukast has broader implications for diseases such as fibrosis, cardiovascular diseases, cancer, cerebrovascular disease, and immune defense. This expanded understanding highlights montelukast's potential for repurposing in conditions involving aberrant stress mechanisms, including ocular diseases marked by inflammation, oxidative stress, ER stress, and apoptosis, among several others. This review delves into montelukast's therapeutic mechanisms across various diseases, draws parallels to ocular conditions, and examines clinical trials and associated adverse effects to underscore the unmet need for cysteinyl LT receptor antagonism by montelukast as an effective therapy for visual deficits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
- Department of Ophthalmology, Anatomy & Neurobiology, Neuroscience Institute, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
ORCID-Profile: Rajashekhar Gangaraju
Förderung
- NEI NIH HHS
Zitieren
APA
Seetharaman, A. T. M., Owens, C. E., & Gangaraju, R. (2024). Cysteinyl Leukotriene Receptor Antagonism by Montelukast to Treat Visual Deficits. Journal of Ocular Pharmacology and Therapeutics. https://doi.org/10.1089/jop.2024.0111
Vancouver
Seetharaman ATM, Owens CE, Gangaraju R. Cysteinyl Leukotriene Receptor Antagonism by Montelukast to Treat Visual Deficits. Journal of Ocular Pharmacology and Therapeutics. 2024. doi:10.1089/jop.2024.0111
BibTeX
@article{Seetharaman2024,
author = {Seetharaman, Amritha T M and Owens, Caroline E and Gangaraju, Rajashekhar},
title = {Cysteinyl Leukotriene Receptor Antagonism by Montelukast to Treat Visual Deficits},
journal = {Journal of Ocular Pharmacology and Therapeutics},
year = {2024},
doi = {10.1089/jop.2024.0111}
}
EUVIMED